Last reviewed · How we verify

NCT04791150

Rheumatologic Adverse Events and Cancer Immunotherapy

Status unknown NA Last updated 10 May 2021
What this trial tests

NA trial testing Fill in a form in Oncology in 400 participants. Status unknown.

Timeline
7 May 2021
Primary endpoint
7 July 2022
7 November 2022

Quick facts

Lead sponsorPoitiers University Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment400
Start date7 May 2021
Primary completion7 July 2022
Estimated completion7 November 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with Oncology or Autoimmunity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, every patient with cancer who is going to be treated by immunotherapy will fill in a form. In this form, we try to determine if he presents rheumatologic complications of his immunotherapy. If the patient answers yes to one question on the form, the patient will be see in rheumatologic consultation to explore his clinical signs. The number of patients referred in consultation thanks to this questionnaire will be compared to the number of patients who would have been spontaneously referred by the oncologist. The aim of this questionnaire is to optimise the management of rheumatological effects secondary to immunotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Oncology

Currently open trials in the same condition.

Other Poitiers University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing